Related Experiment Video
Updated: Aug 6, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Practical Updates and Diagnostic Challenges in Endometrial Carcinoma.
Gulisa Turashvili1, Krisztina Hanley1
1From the Department of Pathology, Emory University Hospital, Atlanta, Georgia.
This review addresses standardization challenges in endometrial carcinoma pathology. It offers practical guidance on grossing, staging, and ancillary testing for accurate diagnosis and reporting.
Area of Science:
- Gynecologic Pathology
- Oncologic Pathology
Background:
- Clinical management of endometrial carcinoma relies heavily on pathologic evaluation of surgical specimens.
- Current practices in grossing, sampling, diagnosis, staging, reporting, and ancillary testing present standardization challenges.
Approach:
- Comprehensive review of existing literature, International Society of Gynecological Pathologists recommendations, and consensus guidelines.
- Focus on standardized grossing, key morphologic findings for reporting and staging, and diagnostic/prognostic use of ancillary testing.
Key Points:
- Summarizes essential aspects of grossing and sampling for microscopic examination.
- Highlights key morphologic parameters for reporting and staging endometrial carcinomas.
- Discusses differential diagnosis of low-grade and high-grade endometrial carcinomas using morphologic features and immunoprofiles.
Conclusions:
- Addresses the current status of molecular classification of endometrial carcinoma.
- Reviews human epidermal growth factor receptor 2 testing in serous carcinoma.
- Aims to assist practicing anatomic pathologists in overcoming diagnostic challenges and reporting issues in endometrial carcinoma.
More Related Videos
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023